GlassScriptPhysician profile
Nathan L Graves
NPI 1184653743
$3,028.74
in general payments reported to CMS, 2019-2025
30 companies · $544 in 2025
The $544 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $593 · 2021: $684 · 2022: $499 · 2023: $161 · 2024: $195 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $440.49 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $376.69 | 2019-2022 | |
| Abbvie INC. | $315.27 | 2019-2025 | |
| Pfizer INC. | $200.70 | 2019-2022 | |
| Avation Medical, INC. | $164.07 | 2025 | Vivally System |
| Clarus Therapeutics INC. | $156.69 | 2021 | |
| Verity Pharmaceuticals INC. | $139.89 | 2024-2025 | Trelstar, Tlando |
| Janssen Biotech, INC. | $134.75 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $129.49 | 2019-2022 | |
| Accord Healthcare, INC. | $126.06 | 2022 | |
| Myovant Sciences INC. | $104.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.12 | 2020-2021 | |
| Blue Earth Diagnostics | $79.83 | 2020-2024 | |
| Endo Pharmaceuticals INC. | $67.59 | 2020-2023 | Xiaflex, Aveed |
| Olympus America INC. | $56.82 | 2021-2025 | Itind System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $50.17 | 2020-2023 | Axonics |
| Coloplast Corp | $47.61 | 2020-2021 | |
| Progenics Pharmaceuticals, INC. | $44.03 | 2022-2025 | |
| Urogen Pharma, INC. | $42.28 | 2021-2025 | |
| Travere Therapeutics, INC. | $40.77 | 2019-2020 | |
| Mission Pharmacal Company | $39.01 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $36.44 | 2022 | |
| Telix Pharmaceuticals | $29.19 | 2025 | Illuccix |
| Ferring Pharmaceuticals INC. | $29.09 | 2025 | Adstiladrin |
| Teleflex LLC | $19.27 | 2025 | Deknatel |
| Myriad Genetic Laboratories, INC. | $18.93 | 2025 | Prolaris |
| Biocompatibles, INC. | $17.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2023 | Seglentis |
| Zyla Life Sciences, INC. | $13.18 | 2020 | |
| Isoray, INC | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.